{
    "info": {
        "nct_id": "NCT04868604",
        "official_title": "A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer",
        "inclusion_criteria": "* Signed informed consent;\n* ≥18 years of age;\n* Eastern Cooperative Oncology Group performance status of 0 to 2;\n* Life expectancy >6 months;\n* Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa);\n* Positive 64Cu-SAR-bisPSMA PET/CT scan, where 64Cu-SAR-bisPSMA uptake (standardized uptake value [SUV] max) of at least 1 known lesion is higher than that of the liver on the 1 hour positron emission tomography (PET)/computed tomography (CT) scan;\n* Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L);\n* Have progressive metastatic castration-resistant prostate cancer (mCRPC) despite prior androgen deprivation therapy and at least either enzalutamide and/or abiraterone (or other such androgen receptor pathway inhibitors). Documented progressive mCRPC will be based on at least 1 of the following criteria:\n\n  1. Serum/plasma prostate specific antigen (PSA) progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal value for study enrollment is 2.0 ng/mL;\n  2. Soft-tissue progression defined as a ≥20% increase in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since the last treatment directed at the metastatic cancer has started (not including hormonal therapy) or the appearance of 1 or more new lesions;\n  3. Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan.\n* ≥1 metastatic lesion that is present at screening CT, magnetic resonance imaging (MRI), or bone scan imaging obtained ≤28 days prior to enrollment into the study;\n* Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (prior chemotherapy, radiation, immunotherapy, etc.);\n* Participants must have adequate organ function:\n\n  * Bone marrow reserve:\n\n    * White blood cell (WBC) count ≥2.5 x 109/L (2.5 x 109/L is equivalent to 2.5 x 103/μL and 2.5 x K/μL and 2.5 x 103/cc and 2500/μL) OR\n    * Absolute neutrophil count (ANC) ≥1.5 x 109 /L (1.5 x 109 /L is equivalent to 1.5 x 103 /μL and 1.5 x K/μL and 1.5 x 103 /cc and 1500/μL);\n  * Platelets ≥100 x 109 /L (100 x 109 /L is equivalent to 100 x 103 /μL and 100 x K/μL and 100 x 103 /cc and 100,000/μL);\n  * Hemoglobin ≥9 g/dL (5.59 mmol/L);\n  * Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3 x ULN is permitted;\n  * Alanine aminotransferase or aspartate aminotransferase ≤3.0 x ULN OR ≤5.0 x ULN for participants with liver metastases;\n  * Creatinine clearance or estimated glomerular filtration rate ≥50 mL/min\n* For participants who are human immunodeficiency virus infected: Participant must be healthy and have a low risk of Acquired Immune Deficiency Syndrome related outcomes in the opinion of the Investigator;\n* For participants who have partners of childbearing potential: Partner and/or participant must use a method of birth control with adequate barrier protection.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Major surgery within 12 weeks prior to enrollment into the study;\n* Brain metastasis;\n* Histologic diagnosis of small cell or neuroendocrine prostate cancer;\n* Prior history of leukemia or Myelodysplastic Syndrome;\n* Diagnosis of Deep Vein Thrombosis or Pulmonary Embolism within 4 weeks prior to enrollment into the study;\n* Unmanageable urinary tract obstruction;\n* Evidence of progressive lesion(s) on MRI and/or CT (according to Response Evaluation Criteria in Solid Tumors V1.1) that is prostate-specific membrane antigen (PSMA) negative on the 1 hour 64Cu-SAR-bisPSMA PET/CT scan as determined at screening;\n* Previous treatment with a systemic radionuclide, including 177Lu, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Actinium-225, Iodine-131 within 6 months or in case of Radium-223 within 3 months of treatment initiation (Day 0) without prior approval of the medical monitor;\n* Previous treatment with any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 4 weeks prior to treatment on study with the exception of Luteinizing Hormone Releasing Hormone, any other androgen deprivation therapy (ADT) (if ADT is discontinued prior to enrolment, 14 days must elapse after abiraterone discontinuation and 28 days after enzalutamide before participant can be enrolled) or low dose corticosteroids;\n* Previous treatment with any investigational agents within 4 weeks prior enrollment into the study;\n* Known hypersensitivity to the components of the investigational products or its analogues;\n* Transfusion for the sole purpose of making a participant eligible for study inclusion;\n* Spinal metastasis with symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression;\n* Concurrent serious medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation;\n* Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer, superficial bladder cancer;\n* Any condition or personal situation that would pose an unacceptable radiation safety risk (as per institution guidelines, state and/or national regulations) to the participant or carer at the time of release following the completion of therapy (e.g. uncontrolled urinary incontinence, high dependency care);\n* Participants in whom it is known that external beam radiation therapy is scheduled after enrollment into the study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants must have adequate organ function:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed informed consent;",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥18 years of age;",
            "criterions": [
                {
                    "exact_snippets": "≥18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group performance status of 0 to 2;",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group performance status of 0 to 2",
                    "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy >6 months;",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy >6 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa);",
            "criterions": [
                {
                    "exact_snippets": "Histological, pathological, and/or cytological confirmation of Prostate cancer (PCa)",
                    "criterion": "prostate cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": [
                                "histological",
                                "pathological",
                                "cytological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L);",
            "criterions": [
                {
                    "exact_snippets": "Castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L)",
                    "criterion": "serum/plasma testosterone",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 50,
                                        "unit": "ng/dL"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 1.7,
                                        "unit": "nmol/L"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive 64Cu-SAR-bisPSMA PET/CT scan, where 64Cu-SAR-bisPSMA uptake (standardized uptake value [SUV] max) of at least 1 known lesion is higher than that of the liver on the 1 hour positron emission tomography (PET)/computed tomography (CT) scan;",
            "criterions": [
                {
                    "exact_snippets": "Positive 64Cu-SAR-bisPSMA PET/CT scan",
                    "criterion": "64Cu-SAR-bisPSMA PET/CT scan",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "64Cu-SAR-bisPSMA uptake (standardized uptake value [SUV] max) of at least 1 known lesion is higher than that of the liver",
                    "criterion": "64Cu-SAR-bisPSMA uptake (SUV max) in at least 1 known lesion",
                    "requirements": [
                        {
                            "requirement_type": "comparison to liver",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "liver SUV max"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on the 1 hour positron emission tomography (PET)/computed tomography (CT) scan",
                    "criterion": "timing of PET/CT scan",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "1 hour post-injection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Serum/plasma prostate specific antigen (PSA) progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal value for study enrollment is 2.0 ng/mL;",
            "criterions": [
                {
                    "exact_snippets": "Serum/plasma prostate specific antigen (PSA) progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior",
                    "criterion": "PSA progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": "2 consecutive increases over a previous reference value measured at least 1 week prior"
                        }
                    ]
                },
                {
                    "exact_snippets": "The minimal value for study enrollment is 2.0 ng/mL",
                    "criterion": "PSA level",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.0,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan.",
            "criterions": [
                {
                    "exact_snippets": "Progression of bone disease: evaluable disease",
                    "criterion": "bone disease",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evaluable disease",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Progression of bone disease: ... new bone lesions(s) by bone scan.",
                    "criterion": "bone lesions by bone scan",
                    "requirements": [
                        {
                            "requirement_type": "new lesions",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Soft-tissue progression defined as a ≥20% increase in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since the last treatment directed at the metastatic cancer has started (not including hormonal therapy) or the appearance of 1 or more new lesions;",
            "criterions": [
                {
                    "exact_snippets": "Soft-tissue progression defined as a ≥20% increase in the sum of the diameter (SOD) ... of all target lesions based on the smallest SOD since the last treatment directed at the metastatic cancer has started (not including hormonal therapy)",
                    "criterion": "soft-tissue progression (sum of diameters of all target lesions)",
                    "requirements": [
                        {
                            "requirement_type": "change from baseline",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "reference point",
                            "expected_value": "smallest SOD since the last treatment directed at the metastatic cancer has started (not including hormonal therapy)"
                        }
                    ]
                },
                {
                    "exact_snippets": "appearance of 1 or more new lesions",
                    "criterion": "new lesions",
                    "requirements": [
                        {
                            "requirement_type": "appearance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesions"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥1 metastatic lesion that is present at screening CT, magnetic resonance imaging (MRI), or bone scan imaging obtained ≤28 days prior to enrollment into the study;",
            "criterions": [
                {
                    "exact_snippets": "≥1 metastatic lesion that is present at screening CT, magnetic resonance imaging (MRI), or bone scan imaging",
                    "criterion": "metastatic lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "CT",
                                "magnetic resonance imaging (MRI)",
                                "bone scan imaging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "imaging obtained ≤28 days prior to enrollment into the study",
                    "criterion": "imaging timing",
                    "requirements": [
                        {
                            "requirement_type": "time_since_imaging",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have progressive metastatic castration-resistant prostate cancer (mCRPC) despite prior androgen deprivation therapy and at least either enzalutamide and/or abiraterone (or other such androgen receptor pathway inhibitors). Documented progressive mCRPC will be based on at least 1 of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "progressive metastatic castration-resistant prostate cancer (mCRPC)",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "metastatic castration-resistant"
                        },
                        {
                            "requirement_type": "progression_status",
                            "expected_value": "progressive"
                        }
                    ]
                },
                {
                    "exact_snippets": "despite prior androgen deprivation therapy",
                    "criterion": "androgen deprivation therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least either enzalutamide and/or abiraterone (or other such androgen receptor pathway inhibitors)",
                    "criterion": "androgen receptor pathway inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (prior chemotherapy, radiation, immunotherapy, etc.);",
            "criterions": [
                {
                    "exact_snippets": "Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies (prior chemotherapy, radiation, immunotherapy, etc.)",
                    "criterion": "clinically significant toxicities related to prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bone marrow reserve:",
            "criterions": [
                {
                    "exact_snippets": "Bone marrow reserve",
                    "criterion": "bone marrow reserve",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "sufficient"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥1.5 x 109 /L (1.5 x 109 /L is equivalent to 1.5 x 103 /μL and 1.5 x K/μL and 1.5 x 103 /cc and 1500/μL);",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥1.5 x 109 /L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500000000.0,
                                "unit": "/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥100 x 109 /L (100 x 109 /L is equivalent to 100 x 103 /μL and 100 x K/μL and 100 x 103 /cc and 100,000/μL);",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥100 x 109 /L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9 /L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN). For participants with known Gilbert's Syndrome ≤3 x ULN is permitted;",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤1.5 x the institutional upper limit of normal (ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "For participants with known Gilbert's Syndrome ≤3 x ULN is permitted",
                    "criterion": "total bilirubin in participants with known Gilbert's Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥9 g/dL (5.59 mmol/L);",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥9 g/dL (5.59 mmol/L)",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase or aspartate aminotransferase ≤3.0 x ULN OR ≤5.0 x ULN for participants with liver metastases;",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase ... ≤3.0 x ULN OR ≤5.0 x ULN for participants with liver metastases",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase ... ≤3.0 x ULN OR ≤5.0 x ULN for participants with liver metastases",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alanine aminotransferase or aspartate aminotransferase ... ≤5.0 x ULN for participants with liver metastases",
                    "criterion": "alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in participants with liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance or estimated glomerular filtration rate ≥50 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ... ≥50 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "estimated glomerular filtration rate ≥50 mL/min",
                    "criterion": "estimated glomerular filtration rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For participants who have partners of childbearing potential: Partner and/or participant must use a method of birth control with adequate barrier protection.",
            "criterions": [
                {
                    "exact_snippets": "participants who have partners of childbearing potential",
                    "criterion": "partner's childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Partner and/or participant must use a method of birth control with adequate barrier protection",
                    "criterion": "birth control method with barrier protection",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequate barrier protection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For participants who are human immunodeficiency virus infected: Participant must be healthy and have a low risk of Acquired Immune Deficiency Syndrome related outcomes in the opinion of the Investigator;",
            "criterions": [
                {
                    "exact_snippets": "human immunodeficiency virus infected",
                    "criterion": "HIV infection status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participant must be healthy",
                    "criterion": "general health status",
                    "requirements": [
                        {
                            "requirement_type": "health status",
                            "expected_value": "healthy"
                        }
                    ]
                },
                {
                    "exact_snippets": "low risk of Acquired Immune Deficiency Syndrome related outcomes in the opinion of the Investigator",
                    "criterion": "risk of AIDS-related outcomes",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "low"
                        },
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Transfusion for the sole purpose of making a participant eligible for study inclusion;",
            "criterions": [
                {
                    "exact_snippets": "Transfusion for the sole purpose of making a participant eligible for study inclusion",
                    "criterion": "transfusion",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": "sole purpose of making a participant eligible for study inclusion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Spinal metastasis with symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression;",
            "criterions": [
                {
                    "exact_snippets": "Spinal metastasis with symptomatic cord compression",
                    "criterion": "spinal metastasis with symptomatic cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical or radiologic findings indicative of impending cord compression",
                    "criterion": "impending cord compression (clinical or radiologic findings)",
                    "requirements": [
                        {
                            "requirement_type": "evidence of impending cord compression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any condition or personal situation that would pose an unacceptable radiation safety risk (as per institution guidelines, state and/or national regulations) to the participant or carer at the time of release following the completion of therapy (e.g. uncontrolled urinary incontinence, high dependency care);",
            "criterions": [
                {
                    "exact_snippets": "Any condition or personal situation that would pose an unacceptable radiation safety risk ... to the participant or carer at the time of release following the completion of therapy",
                    "criterion": "radiation safety risk at time of release after therapy",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "not unacceptable"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled urinary incontinence",
                    "criterion": "urinary incontinence",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "not uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "high dependency care",
                    "criterion": "dependency care level",
                    "requirements": [
                        {
                            "requirement_type": "dependency level",
                            "expected_value": "not high"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants in whom it is known that external beam radiation therapy is scheduled after enrollment into the study.",
            "criterions": [
                {
                    "exact_snippets": "Participants in whom it is known that external beam radiation therapy is scheduled after enrollment into the study.",
                    "criterion": "external beam radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "scheduled after enrollment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concurrent serious medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation;",
            "criterions": [
                {
                    "exact_snippets": "Concurrent serious medical conditions",
                    "criterion": "serious medical conditions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association class III or IV congestive heart failure",
                    "criterion": "congestive heart failure (NYHA class III or IV)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "history of congenital prolonged QT syndrome",
                    "criterion": "congenital prolonged QT syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis B or C",
                    "criterion": "hepatitis B or C",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "other significant co-morbid conditions that in the opinion of the Investigator would impair study participation or cooperation",
                    "criterion": "other significant co-morbid conditions impairing study participation or cooperation",
                    "requirements": [
                        {
                            "requirement_type": "impact on study participation or cooperation",
                            "expected_value": "would impair"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unmanageable urinary tract obstruction;",
            "criterions": [
                {
                    "exact_snippets": "Unmanageable urinary tract obstruction",
                    "criterion": "urinary tract obstruction",
                    "requirements": [
                        {
                            "requirement_type": "manageability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with a systemic radionuclide, including 177Lu, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Actinium-225, Iodine-131 within 6 months or in case of Radium-223 within 3 months of treatment initiation (Day 0) without prior approval of the medical monitor;",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with a systemic radionuclide, including 177Lu, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Actinium-225, Iodine-131 within 6 months",
                    "criterion": "previous treatment with systemic radionuclide (177Lu, Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Actinium-225, Iodine-131)",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in case of Radium-223 within 3 months of treatment initiation (Day 0)",
                    "criterion": "previous treatment with Radium-223",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of progressive lesion(s) on MRI and/or CT (according to Response Evaluation Criteria in Solid Tumors V1.1) that is prostate-specific membrane antigen (PSMA) negative on the 1 hour 64Cu-SAR-bisPSMA PET/CT scan as determined at screening;",
            "criterions": [
                {
                    "exact_snippets": "Evidence of progressive lesion(s) on MRI and/or CT (according to Response Evaluation Criteria in Solid Tumors V1.1)",
                    "criterion": "progressive lesion(s)",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "MRI",
                                "CT"
                            ]
                        },
                        {
                            "requirement_type": "progression criteria",
                            "expected_value": "Response Evaluation Criteria in Solid Tumors V1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "prostate-specific membrane antigen (PSMA) negative on the 1 hour 64Cu-SAR-bisPSMA PET/CT scan as determined at screening",
                    "criterion": "prostate-specific membrane antigen (PSMA) status on 1 hour 64Cu-SAR-bisPSMA PET/CT scan",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "1 hour"
                        },
                        {
                            "requirement_type": "tracer",
                            "expected_value": "64Cu-SAR-bisPSMA"
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": "PET/CT"
                        },
                        {
                            "requirement_type": "assessment timepoint",
                            "expected_value": "screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 12 weeks prior to enrollment into the study;",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 12 weeks prior to enrollment into the study;",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of leukemia or Myelodysplastic Syndrome;",
            "criterions": [
                {
                    "exact_snippets": "Prior history of leukemia",
                    "criterion": "leukemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of ... Myelodysplastic Syndrome",
                    "criterion": "Myelodysplastic Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with any investigational agents within 4 weeks prior enrollment into the study;",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with any investigational agents within 4 weeks prior enrollment into the study",
                    "criterion": "previous treatment with investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to enrollment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologic diagnosis of small cell or neuroendocrine prostate cancer;",
            "criterions": [
                {
                    "exact_snippets": "Histologic diagnosis of small cell or neuroendocrine prostate cancer",
                    "criterion": "prostate cancer histology",
                    "requirements": [
                        {
                            "requirement_type": "histologic diagnosis",
                            "expected_value": [
                                "small cell",
                                "neuroendocrine"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous treatment with any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 4 weeks prior to treatment on study with the exception of Luteinizing Hormone Releasing Hormone, any other androgen deprivation therapy (ADT) (if ADT is discontinued prior to enrolment, 14 days must elapse after abiraterone discontinuation and 28 days after enzalutamide before participant can be enrolled) or low dose corticosteroids;",
            "criterions": [
                {
                    "exact_snippets": "Previous treatment with any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 4 weeks prior to treatment on study",
                    "criterion": "previous systemic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of Luteinizing Hormone Releasing Hormone, any other androgen deprivation therapy (ADT) (if ADT is discontinued prior to enrolment, 14 days must elapse after abiraterone discontinuation and 28 days after enzalutamide before participant can be enrolled)",
                    "criterion": "androgen deprivation therapy (ADT) discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "time since abiraterone discontinuation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "time since enzalutamide discontinuation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of ... low dose corticosteroids",
                    "criterion": "low dose corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "use permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer, superficial bladder cancer;",
            "criterions": [
                {
                    "exact_snippets": "Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment.",
                    "criterion": "other malignancies",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "expected impact on life expectancy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "potential to interfere with disease assessment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years",
                    "criterion": "prior history of malignancy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        },
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "adequately treated non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                },
                {
                    "exact_snippets": "superficial bladder cancer",
                    "criterion": "superficial bladder cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "adequately treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of Deep Vein Thrombosis or Pulmonary Embolism within 4 weeks prior to enrollment into the study;",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of Deep Vein Thrombosis ... within 4 weeks prior to enrollment",
                    "criterion": "Deep Vein Thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... Pulmonary Embolism within 4 weeks prior to enrollment",
                    "criterion": "Pulmonary Embolism",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to the components of the investigational products or its analogues;",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to the components of the investigational products or its analogues",
                    "criterion": "hypersensitivity to investigational product components or analogues",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Brain metastasis;",
            "criterions": [
                {
                    "exact_snippets": "Brain metastasis",
                    "criterion": "brain metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* White blood cell (WBC) count ≥2.5 x 109/L (2.5 x 109/L is equivalent to 2.5 x 103/μL and 2.5 x K/μL and 2.5 x 103/cc and 2500/μL) OR",
            "criterions": [
                {
                    "exact_snippets": "White blood cell (WBC) count ≥2.5 x 10^9/L",
                    "criterion": "white blood cell (WBC) count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}